The WHO said Thursday that it's got fielded a number of reports of faux semaglutide — the active component in Novo Nordisk's Wegovy and Ozempic — in all geographic locations of the whole world given that 2022. The patent for semaglutide, the active ingredient in Ozempic and Wegovy, isn’t anticipated to expire until around 2031 at the earlies